NEW YORK, NY, Elion Therapeutics, a biotechnology company, announced it has closed a $81 million Series B funding round.
Elion Therapeutics (formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life-threatening invasive fungal infections (IFIs), announced it has closed a $81 million Series B funding round led by Deerfield Management (Deerfield) and the AMR Action Fund. Additional investors include Illinois Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
